Back to Search Start Over

An Apparatus to Deliver Mannitol Powder for Bronchial Provocation in Children Under Six Years Old.

Authors :
Tang P
Leung SS
Hor E
Ruzycki CA
Carrigy NB
Finlay WH
Brannan JD
Devadason S
Anderson SD
Sly PD
Samnick K
Chan HK
Source :
Journal of aerosol medicine and pulmonary drug delivery [J Aerosol Med Pulm Drug Deliv] 2015 Dec; Vol. 28 (6), pp. 452-61. Date of Electronic Publication: 2015 Apr 06.
Publication Year :
2015

Abstract

Background: Currently bronchial provocation testing (BPT) using mannitol powder cannot be performed in children under 6 years. A primary reason is it is challenging for children at this age to generate a consistent inspiratory effort to inhale mannitol efficiently from a dry powder inhaler. A prototype system, which does not require any inhalation training from the pediatric subject, is reported here. It uses an external source of compressed air to disperse mannitol powder into a commercial holding chamber. Then the subject uses tidal breathing to inhale the aerosol.<br />Method: The setup consists of a commercially available powder disperser and Volumatic™ holding chamber. Taguchi experimental design was used to identify the effect of dispersion parameters (flow rate of compressed air, time compressed air is applied, mass of powder, and the time between dispersion and inhalation) on the fine particle dose (FPD). The prototype was tested in vitro using a USP throat connected to a next generation impactor. The aerosols from the holding chamber were drawn at 10 L/min. A scaling factor for estimating the provoking dose to induce a 15% reduction in forced expiratory volume in 1 second (FEV1) (PD15) was calculated using anatomical dimensions of the human respiratory tract at various ages combined with known dosing values from the adult BPT.<br />Results: Consistent and doubling FPDs were successfully generated based on the Taguchi experimental design. The FPD was reliable over a range of 0.8 (±0.09) mg to 14 (±0.94) mg. The calculated PD15 for children aged 1-6 years ranged from 7.1-30 mg. The FPDs generated from the proposed set up are lower than the calculated PD15 and therefore are not expected to cause sudden bronchoconstriction.<br />Conclusion: A prototype aerosol delivery system has been developed that is consistently able to deliver doubling doses suitable for bronchial provocation testing in young children.

Details

Language :
English
ISSN :
1941-2703
Volume :
28
Issue :
6
Database :
MEDLINE
Journal :
Journal of aerosol medicine and pulmonary drug delivery
Publication Type :
Academic Journal
Accession number :
25844950
Full Text :
https://doi.org/10.1089/jamp.2015.1208